RF Acquisition Corp II Shareholders Approve Nanyang Biologics Business Combination

summarizeSummary

RF Acquisition Corp II shareholders approved the business combination with Nanyang Biologics, but preliminary redemptions of 3.96 million shares could drain nearly half the trust account.

check_boxKey Events · M&A and Partnerships · RFAI

• Business Combination Approved

  The merger with Nanyang Biologics Pte. Ltd. cleared its final major hurdle, with shareholders voting 6,765,584 for and 440,604 against.

• Preliminary Redemptions Near 50%

  Preliminary requests to redeem 3,956,323 ordinary shares were submitted, representing approximately 47.4% of the 8,343,765 shares outstanding, subject to withdrawal or reversal prior to closing.

• Trust Account Impact

  If all preliminary redemptions are completed, the trust account proceeds available to the combined company would be substantially reduced, potentially leaving less cash for operations and growth.

• Closing Conditions Remain

  The closing of the business combination remains subject to satisfaction or waiver of applicable closing conditions, and the final redemption results will be disclosed promptly after closing.

auto_awesomeAnalysis · RFAI · Real Estate & Construction

The final major hurdle for the SPAC merger has been cleared, with shareholders voting overwhelmingly to approve the business combination with Nanyang Biologics Pte. Ltd. The tally was decisive: 6,765,584 shares for versus 440,604 against. However, preliminary redemption requests total 3,956,323 shares — nearly half of the 8,343,765 shares outstanding — which would significantly reduce the trust account proceeds available to the combined company. The final redemption figure remains uncertain until closing, but the high redemption level signals that many shareholders prefer cash over the merger, potentially leaving the post-combination entity with less capital than anticipated.